拨康视云-B(02592) - 公司概况
最后更新于：2025-07-14
| 公司名称 | 拨康视云-B |
| 上市日期 | 2025-07-03 |
| 董事长 | Ni Jinsong |
| 财政年度结算日期 | 1970-01-01 |
| 公司概况 | Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. The Company is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The Company has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011. |
| 上市类型 | 主要上市 |
| 过户处 | 卓佳证券登记有限公司 |
| 公司网址 | http://www.cloudbreakpharma.com |
| 注册地址 | 开曼群岛 |
| 办公地址 | 香港/金钟道89号/力宝中心1座/23楼2308室 |
